DOCSLIB.ORG

Evaluation of Predictive Tests for Screening for Dihydropyrimidine Dehydrogenase Deficiency

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Evaluation of Predictive Tests for Screening for Dihydropyrimidine Dehydrogenase Deficiency The Pharmacogenomics Journal (2013) 13, 389–395 & 2013 Macmillan Publishers Limited All rights reserved 1470-269X/13 www.nature.com/tpj REVIEW Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency MC van Staveren1, H Jan Guchelaar2, ABP van Kuilenburg3, H Gelderblom4 and JG Maring5 5-Fluorouracil (5-FU) is rapidly degraded by dihyropyrimidine dehydrogenase (DPD). Therefore, DPD deficiency can lead to severe toxicity or even death following treatment with 5-FU or capecitabine. Different tests based on assessing DPD enzyme activity, genetic variants in DPYD and mRNA variants have been studied for screening for DPD deficiency, but none of these are implemented broadly into clinical practice. We give an overview of the tests that can be used to detect DPD deficiency and discuss the advantages and disadvantages of these tests. The Pharmacogenomics Journal (2013) 13, 389–395; doi:10.1038/tpj.2013.25; published online 16 July 2013 Keywords: dihyropyrimidine dehydrogenase; 5-fluorouracil; genotyping; pharmacokinetics; phenotyping; uracil INTRODUCTION Pyrimidinemia’, ‘uracil’, ‘capecitabine’, ‘dihydrouracil dehydrogenase The fluoropyrimidine 5-fluorouracil (5-FU) and its prodrug (nadp)’, ‘dihydrouracil dehydrogenase’, ‘dihydropyrimidine dehydrogen- ase’, ‘dihydrouracil dehydrogenase (nad þ )’ and ‘dpd’. The search resulted capecitabine, are the cornerstone of treatment of numerous types in 397, 378, 568 and 28 hits for MEDLINE, EMBASE, Web of Science and of cancer. The use of fluoropyrimidines is associated with Cochrane, respectively. The unique hits collected from these databases numerous side effects, such as myelosuppression, hand-foot were selected and further limited to English language papers from 1980 to syndrome, mucositis, diarrhea and occasionally cardiac toxicity. 1 January 2012. Papers describing studies aimed at testing DPD activity After parenteral administration of 5-FU, 70–90% of the parent and/or DPD deficiency in volunteers or patients were selected. Cross drug is degraded by dihydropyrimidine dehydrogenase (DPD).1–5 references were identified from bibliographies from the selected studies. A small proportion of patients develop extreme toxicity after Only articles that describe the complete performance of the test were administration of a fluoropyrimidine due to a partial or complete included; reviews and papers describing in vitro studies including DPD DPD deficiency and hence a strongly reduced capacity to degrade activity in cancer cells or studies in animals were neglected. The collected publications were divided into three categories, describing tests aimed 5-FU.6–10 In case of complete DPD deficiency, 5FU treatment may 11 at assessing DPD enzyme activity (38 articles), genetic variants in DPYD even result in a lethal outcome. It was initially estimated that in (20 articles) and mRNA variants (3 articles). 3–5% of Caucasians the activity of DPD is strongly reduced due to (epi)genetic variations in the gene encoding DPD.4,12 However, this percentage has been disputed as there is still no consensus Tests aimed at assessing (surrogates for) DPD enzyme activity on the definition of DPD deficiency, and therefore the incidence Several tests have been described to assess the activity of the enzyme of DPD deficiency reported in numerous studies is strongly DPD. dependent on the method used to assess DPD deficiency13 and the cutoff level chosen to define DPD deficiency.5 DPD activity in peripheral blood mononuclear cells (PBMCs). The majority of DPD is reported to be in the liver,1,14 but DPD activity in other tissues such Prospective testing for DPD deficiency in patients might as lymphocytes contribute to metabolism of fluoropyrimidines as well.15 prevent DPD-deficient patients from severe toxicity or even death. The liver DPD activity in patients revealed a strong correlation with DPD In this review, we describe current methods for determination of activity in PBMCs.16 The mean DPD activity in PBMCs of patients with a DPD deficiency. We discuss the potential and limitations of these partial DPD deficiency is approximately 48% to that observed in the tests for routine clinical use. In addition, we have defined normal population due to heterozygosity for a pathological mutation.17 recommendations that can help successful implementation of a The methodology of the test includes incubating isolated lymphocytes pre-emptive testing strategy to predict fluoropyrimidine-related with radioactive labeled 5-FU or thymine after which the degradation toxicity. products are measured by high-performance liquid chromatography (HPLC) with a radioisotope flow detector.2,18–20 A HPLC-electrospray tandem mass spectrometry (HPLC MS/MS) method has also been developed.17,21 The use of a porous graphitic carbon column22 results in METHODS a HPLC process that is highly pH stable compared with the reversed-phase To identify studies describing diagnostic tests to detect DPD deficiency, C-18 column, and the detection limit was at least similar to the C-18 a systematic MEDLINE, EMBASE, Web of Science and Cochrane search columns with considerably shorter analysis time. This method was was conducted using the following combination of MESH terms:, ‘dihydro- validated (Table 1). Evaluation of the stability of DPD in PBMCs indicated pyrimidine dehydrogenase deficiency’, ‘dpd deficiency’, ‘Familial that the DPD activity decreased approximately 50% upon freezing but was 1Department of Pharmacy, Scheper Hospital Emmen and Ro¨pcke Zweers Hospital Hardenberg, Emmen, The Netherlands; 2Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands; 3Laboratory Genetic Metabolic Diseases, Academic Medical Center Amsterdam, University of Amsterdam, Amsterdam, The Netherlands; 4Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands and 5Department of Pharmacy, Diaconessen Hospital Meppel and Bethesda Hospital Hoogeveen, Meppel, The Netherlands. Correspondence: MC van Staveren, Department of Pharmacy, Scheper Hospital Emmen and Ro¨pcke Zweers Hospital Hardenberg, Boermarkeweg 60, Emmen 7824 AA, The Netherlands. E-mail: [email protected] Received 7 November 2012; revised 22 May 2013; accepted 29 May 2013; published online 16 July 2013 390 The Pharmacogenomics Journal (2013), 389 – 395 Table 1. Validation parameters of the diagnostic tests at the enzyme level to screen for DPD deficiency Inter-assay Study n Reference method Recovery Sensitivity Specificity variability Linear Intra-assay variability 24 Mattison et al. 58 volunteers DPD in PBMC ND 100% 96% ‘Reproducible’ ND o5% Genotyping with DHPLC Mattison et al.25 23 volunteers, 8 cancer patients DPD in PBMC ND ND ND ND ND ND Mattison et al.26 258 volunteers DPD in PBMC ND 86% 99% ND ND ND 19 Johnson et al. 100 volunteers, 80 cancer NA 495% ND ND o8% CV Yes o6.5% CV patients 22 Liem et al. 132 volunteers NA 99±2%, 3% CV ND ND o4% CV Yes o3% Lostia et al.21 39 cancer patients HPLC-UV ND ND ND 0.7–5.6% CVa Yes 8.3–1.4% CVa b c van Kuilenburg 28 cancer patients, 1 patient Radioactive 94.4–102.4 99.4–101.6% ND ND 1.7–4.7% CV Yes 1.0–3.2% CV Predictive tests for DPD et al.17 with verified DPYD mutation thymine by HPLC MC van Staveren MS/MS van Kuilenburg 2 cancer patients, unknown NA ND ND ND 9% CV Yes 5% CV et al.18 number healthy volunteers Bi et al.29 4 patients participating in a NA (Relative recovery ND ND 6.73, 6.95, 5.96% ND 7.04, 5.40, 1.24% (RSD phase 1 trial compared with water) (RSD 0.27, 25 and 0.27, 25 and 250 mM) 95.8±2.0 1 mM 95.5±10.9% 250 mM) et al 100 mM Garg et al.34 23 cancer patients, blank plasma NA 93–100 Uracil d, 95–99% ND ND 0.2–7% RSD Yes 0.8–7% RSD uracile, healthy volunteers UH2 Uracil 1.2–9.9% 2.6–9.7% RSD UH2 RSD UH2 Kristensen et al.37 68 CRC patients, 100 healthy IVS þ 1G4A ND 87% 93% ND ND ND controls mutation 5-FU plasma levels Ciccolini et al.28 30 blank plasma samples, one U/UH2 ratio 90% ND ND 10.6, 1212.8% Yes 12, 2.4, 3.3% case report 20 ng ml À 1, 20 ng ml À 1, 75 ng ml À 1, 75 ng ml À 1, 375 ng ml À 1 5-FU 375 ng ml À 1 5-FU 42 Beumer et al. 156 plasma samples obtained LC-MS/MS 93–104% ND ND o2% CV Yes 2.1–3.9% CV from patients; Plasma pool samples di Paolo et al.39 25 CRC patients DPD in PBMC 85 5-FU; 81% 5-FDHU ND ND 5.28–9.44 5-FU; Yes 4.91–6.05% 5-FU; 5.00–9.03 5-FDHU 4.55–6.99% 5-FDHU Remaud et al.36 8 volunteers, blank plasma NA 73±2% Uracil 67±2% ND ND 0.9–2.3% U; Yes 1.3–5.3% U; 1.3–7.1% & UH2; 82±3FUH2% 0.7–5.6% UH2 UH2 2013 Macmillan Publishers Limited van Kuilenburg 30 cancer patients, 18 controls 5-FU loading dose ND 100%f 90%f ND Yes ND et al.8 De´ porte-Fe´ty 1 volunteer, 29 cancer patients DPD in PBMC with ND ND ND 2.5–8.7% Yes 9.5–3.2% et al.40 radiolabeled 5-FU Abbreviations: CRC, colorectal cancer; CV, coefficient of variation; DHPLC, denaturing high-performance liquid chromatography; DPD, dihydropyrimidine dehydrogenase; 5-FDHU, 5-fluoro-5,6-dihydrouracil; FUH2, dihydrofluorouracil; 5-FU, 5-fluorouracil; HPLC, high-performance liquid chromatography; LC-MS/MS, liquid chromatography-tandem mass spectrometry; NA, not applicable; ND, not determinated; PBMC, peripheral blood mononuclear cell; RSD, relative standard variation; U, uracil; UH2, dihydrouracil; UV, ultraviolet. a5-FU concentration range of 0.156, 0.195, 078 and 1.95 mgmlÀ 1. bInter-assay recovery at low, normal and high concentration of dihydrothymine.
Load more

Recommended publications
  • Thesis Final
    CHARACTERIZATION OF ADENOSINE NUCLEOSIDASE FROM ALASKA PEA SEEDS by Abdullah K. Shamsuddin A Thesis Submitted to the Faculty of the College of Graduate Studies at Middle Tennessee State University in Partial Fulfillment of the Requirements for the Degree of Master of Science in Chemistry Middle Tennessee State University August 2015 Thesis Committee: Dr. Paul C. Kline, Chair Dr. Donald A. Burden Dr. Kevin L. Bicker I dedicate this research to my parents, my sisters, and my brother. I love you all. ii" " ACKNOWLEDGEMENTS I would like to express my sincere gratitude to my advisor, Dr. Paul C. Kline, for his guidance, support, and ongoing encouragement throughout this project. I also wish to thank my committee members, Dr. Donald A. Burden and Dr. Kevin L. Bicker, for their advice and insightful comments. In addition, I would like to thank all the staff and faculty of the Department of Chemistry for their contribution to the success of this study. Lastly, I wish to thank my family and my friends, without whom none of my accomplishments would have been possible. Thank you for you endless support, concern, love, and prayer. iii" " ABSTRACT Adenosine nucleosidase was purified from Alaska pea seeds five days after germination. A 4-fold purification has been reached with a 1.3 % recovery. The subunit molecular weight of adenosine nucleosidase was determined by mass spectrometry to be 26,103 daltons. The number of subunits was 1. The Michaelis constant, Km, and the maximum velocity, V max, for adenosine were determined to be 137 ± 48 µM, and 0.34 ± 0.02 µM/min respectively.
    [Show full text]
  • Pyrimidine Base Degradation in Cultured Murine C-1300 Neuroblastoma Cells and in Situ Tumors
    Pyrimidine base degradation in cultured murine C-1300 neuroblastoma cells and in situ tumors. M Tuchman, … , M L Ramnaraine, B L Mirkin J Clin Invest. 1988;81(2):425-430. https://doi.org/10.1172/JCI113336. Research Article Dihydropyrimidine dehydrogenase (DPD), the initial, rate-limiting step in pyrimidine degradation, was studied in two cell lines of murine neuroblastoma (MNB-T1 and MNB-T2) that were derived from C-1300 MNB tumor carried in A/J mice. The MNB-T2 (low malignancy) cell line was originally derived from the in situ tumor and carried in tissue culture for more than 100 passages; the MNB-T1 (high malignancy) line consisted of a new sub-culture that was also established from the in situ MNB tumor. DPD activity was determined in cytosolic preparations of MNB utilizing high performance liquid chromatography to separate the radiolabeled substrate ([2-14C]thymine) from [2-14C]dihydrothymine. The apparent affinity of DPD for NADPH in MNB cells (Km approximately 0.08 mM) was identical to that of A/J mouse brain and liver. The DPD activity of the high malignancy (MNB-T1) cell line was 14.3% of that observed in the low malignancy (MNB-T2) line. In situ tumors formed after implantation of high malignancy (MNB-T1) cells into A/J mice had only 25.2% of the DPD activity observed in tumors derived from low malignancy (MNB-T2) cells. When MNB-T2 cells were injected into naive A/J mice, tumors developed in only 68% of animals, the tumor growth rate was slow and a mortality of 20% was observed.
    [Show full text]
  • (10) Patent No.: US 8119385 B2
    US008119385B2 (12) United States Patent (10) Patent No.: US 8,119,385 B2 Mathur et al. (45) Date of Patent: Feb. 21, 2012 (54) NUCLEICACIDS AND PROTEINS AND (52) U.S. Cl. ........................................ 435/212:530/350 METHODS FOR MAKING AND USING THEMI (58) Field of Classification Search ........................ None (75) Inventors: Eric J. Mathur, San Diego, CA (US); See application file for complete search history. Cathy Chang, San Diego, CA (US) (56) References Cited (73) Assignee: BP Corporation North America Inc., Houston, TX (US) OTHER PUBLICATIONS c Mount, Bioinformatics, Cold Spring Harbor Press, Cold Spring Har (*) Notice: Subject to any disclaimer, the term of this bor New York, 2001, pp. 382-393.* patent is extended or adjusted under 35 Spencer et al., “Whole-Genome Sequence Variation among Multiple U.S.C. 154(b) by 689 days. Isolates of Pseudomonas aeruginosa” J. Bacteriol. (2003) 185: 1316 1325. (21) Appl. No.: 11/817,403 Database Sequence GenBank Accession No. BZ569932 Dec. 17. 1-1. 2002. (22) PCT Fled: Mar. 3, 2006 Omiecinski et al., “Epoxide Hydrolase-Polymorphism and role in (86). PCT No.: PCT/US2OO6/OOT642 toxicology” Toxicol. Lett. (2000) 1.12: 365-370. S371 (c)(1), * cited by examiner (2), (4) Date: May 7, 2008 Primary Examiner — James Martinell (87) PCT Pub. No.: WO2006/096527 (74) Attorney, Agent, or Firm — Kalim S. Fuzail PCT Pub. Date: Sep. 14, 2006 (57) ABSTRACT (65) Prior Publication Data The invention provides polypeptides, including enzymes, structural proteins and binding proteins, polynucleotides US 201O/OO11456A1 Jan. 14, 2010 encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides.
    [Show full text]
  • Induced Alterations in the Urine Metabolome in Cardiac Surgery
    www.nature.com/scientificreports OPEN Bretschneider solution- induced alterations in the urine metabolome in cardiac surgery Received: 16 August 2018 Accepted: 1 November 2018 patients Published: xx xx xxxx Cheng-Chia Lee1,3, Ya-Ju Hsieh 2, Shao-Wei Chen3,4, Shu-Hsuan Fu2, Chia-Wei Hsu 2, Chih-Ching Wu 2,5,6, Wei Han7, Yunong Li7, Tao Huan7, Yu-Sun Chang2,6,8, Jau-Song Yu2,9,10, Liang Li7, Chih-Hsiang Chang1,3 & Yi-Ting Chen 1,2,11,12 The development of Bretschneider’s histidine-tryptophan-ketoglutarate (HTK) cardioplegia solution represented a major advancement in cardiac surgery, ofering signifcant myocardial protection. However, metabolic changes induced by this additive in the whole body have not been systematically investigated. Using an untargeted mass spectrometry-based method to deeply explore the urine metabolome, we sought to provide a holistic and systematic view of metabolic perturbations occurred in patients receiving HTK. Prospective urine samples were collected from 100 patients who had undergone cardiac surgery, and metabolomic changes were profled using a high-performance chemical isotope labeling liquid chromatography-mass spectrometry (LC-MS) method. A total of 14,642 peak pairs or metabolites were quantifed using diferential 13C-/12C-dansyl labeling LC-MS, which targets the amine/phenol submetabolome from urine specimens. We identifed 223 metabolites that showed signifcant concentration change (fold change > 5) and assembled several potential metabolic pathway maps derived from these dysregulated metabolites. Our data indicated upregulated histidine metabolism with subsequently increased glutamine/glutamate metabolism, altered purine and pyrimidine metabolism, and enhanced vitamin B6 metabolism in patients receiving HTK.
    [Show full text]
  • Particular Metabolic Profile of Patient with Total
    International Journal of Pharmaceutical Science and Health Care Issue 5, Vol. 1 (Jan-Feb. 2015) Available online on http://www.rspublication.com/ijphc/index.html ISSN 2249 – 5738 PARTICULAR METABOLIC PROFILE OF PATIENT WITH TOTAL DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY (DPD) Saif Eddine GAMAOUNa,b, Nissem ABDEJALLILa, Mhamed Ali HAMZAb, Saad SAGUEMa aLaboratory of Metabolic Biophysics, Professional and Applied Environmental Toxicology, Medicine faculty of Sousse, Mohamed Karoui street, Sousse 4002, Tunisia bDepartment of chemistry, sciences faculty of Monastir, Environment street, Monastir 5019, Tunisia *Author for correspondence at present address: Saif Eddine GAMAOUN Higher Institute of Technological Studies (ISET) Ksar Hellal-Hadj Ali Soua street-5070-Ksar Hellal,Tunisia Fonction : Engineer of analytical chemistry and instrumentation - Assistant teacher in ISET Ksar Hellal - Tunisia Tel.: (+216) 73 475 900 / (+216) 98 685 958 Fax: (+216) 73 475 163 E-mail: saifeddineg @ yahoo.fr ABSTRACT 5-Fluorouracil (5-FU) remains one of the most used chemotherapeutics agents in the treatment of several types of cancers. Its use could nevertheless, raise a problem of pharmacovigilance. It may engender a very grave toxicity which can be fatal at certain patient's presenting an enzymatic deficit with dihydropyrimidine dehydrogenase (DPD). The identification of the subjects at risk through the detection of a partial or total deficit before starting the treatment with 5-FU, could allow to adapt individually the prescribed dose, to optimize the therapeutic efficacy and reduce potential toxicities at expanding patients of a partial deficit to DPD. Such a screening would especially become more important when it is about a complete deficit in DPD. Such metabolic abnormality whose frequency is of the order of one per thousand, would indeed constitute a contraindication absolved from any chemotherapy with 5-FU (mortal toxicities).
    [Show full text]
  • Possible Prediction of Adverse Reactions to Pyrimidine Chemotherapy from Urinary Pyrimidine Levels and a Case of Asymptomatic Adult Dihydropyrimidinuria1
    Vol. 2, 1937-1 941, December 1996 Clinical Cancer Research 1937 Possible Prediction of Adverse Reactions to Pyrimidine Chemotherapy from Urinary Pyrimidine Levels and a Case of Asymptomatic Adult Dihydropyrimidinuria1 Katsuo Hayashi,2 Kiyoshi Kidouchi, INTRODUCTION Satoshi Sumi, Masashi Mizokami, Etsuro Onto, Pyrimidine chemotherapy agents such as 5-FU3 are used widely but can occasionally cause serious adverse reactions. In Kazunoni Kumada, Ryuzo Ueda, and pyrimidine metabolism, uracil and thymine are first converted to Yoshino Wada dihydropyrimidines (dihydrouracil and dihydrothymine) by Departments of Medicine [K. H., K. Ku.] and Pediatrics [K. Ki.], DPD and then are metabolized to 3-ureidopropionic acid and Nagoya City Higashi General Hospital, 2-23 Wakamizu 1-chome, 3-ureidoisobutyric acid, respectively, by dihydropyrimidinase. Chikusa-ku, Nagoya 464, Japan, and Department of Pediatrics [S. S., These compounds are converted subsequently into 3-alanine Y. W.] and Second Department of Medicine [M. M., E. 0., R. U.], Nagoya City University Medical School. Nagoya, Japan and -arninoisobutyric acid, respectively ( 1). Because about 80% of an administered dose of 5-FU is degraded by this pathway, there is a possibility of adverse reactions occurring as ABSTRACT a result of DPD or dihydrophrimidinase deficiency. The value of Deficiency of dihydropyrimidine dehydrogenase or di- measuring peripheral blood monocyte DPD activity before ad- hydropyrimidinase, enzymes that catalyze the breakdown of ministering 5-FU has been suggested in Western countries (2- pyrimidine chemotherapy agents such as 5-fluorouracil, 6), but DPD deficiency has not been reported in Japan. may cause serious adverse reactions to these agents. We Using a method that permits analysis of dihydrouracil and attempted to establish the reference range for urinary pyri- uracil in small volumes of urine, we previously screened Japa- midines in adults to detect individuals with abnormal py- nese infants for abnormalities of pyrimidine metabolism and rimidine metabolism.
    [Show full text]
  • Catabolism of Xanthine and Uracil in Tumor-Bearing Rats'1
    Catabolism of Xanthine and Uracil in Tumor-bearing Rats'1 CHUNGWu ANDJEREM. BAUER (Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan) SUMMARY The urinary excretion of allantoin and uric acid was greatly increased in rats bear ing Walker carcinoma 256. The increase was greater with more advanced tumor growth. A similar increase was also observed in the allantoin concentration of the plasma and liver of these rats. An increase in the RNA and DNA content and a decrease in the RNA/DNA ratio were found in the muscle of the tumor-bearing animals. Liver xan- thine oxidase activity was increased in rats bearing Walker 256 and Guerin carcinomas and NovikofT and Morris 3683 hepatomas but was unchanged in rats bearing Jensen sarcoma, Morris 5123, and Morris 3924-A hepatomas, when compared with their re spective controls fed ad libitum. Liver uracil reductase activity showed a decrease in rats bearing Morris 5123 and Morris 3924-A hepatomas but no change in rats bearing Walker carcinoma 256 and Novikoff and Morris 3683 hepatomas. These findings indi cate that the effect of different tumors on a given enzyme in the host system need not be qualitatively uniform. Finally, unlike the other hepatomas tested, Morris 5123 hepatoma was found to possess xanthine oxidase activity approaching that found in a normal liver. That the growth of a malignant tumor causes tivity has not been studied in detail in tumor-bear many disturbances in the metabolism of the host ing rats. A survey of this enzyme activity in the is well known.
    [Show full text]
  • Ung)-Initiated Dna Base Excision Repair in The
    ELUCIDATING A ROLE FOR URACIL DNA GLCYOSYLASE (UNG)-INITIATED DNA BASE EXCISION REPAIR IN THE CELLULAR SENSITIVITY TO THE ANTIFOLATE, PEMETREXED by LACHELLE DAWN WEEKS Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Dissertation Advisor: Dr. Stanton L. Gerson Department of Pathology CASE WESTERN RESERVE UNIVERSITY January 2014 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of ___________Lachelle Dawn Weeks__________ candidate for the Doctor of Philosophy degree*. (signed) ______Shigemi Matsuyama__________ (chair of the committee) _______Alexandru Almasan__________ _________Ruth A. Keri______________ _________George R. Stark__________ __________Stanton L. Gerson________ (date) _____August 23, 2013____________ * We also certify that written approval has been obtained for any proprietary material contrained therein. i Dedication To Clarissa Williams and Wesley Weeks. ii Table of Contents Dedication……………….........................................................................................ii Table of Contents……………………………………………………………………….iii List of Tables…………………………………………………………….………………vi List of Figures..…………………………………………………………………………vii Acknowledgements……………………………………………………………………..xi List of Abbreviations…………………………………………………………………...xiii Abstract…………………………………………………………………………………..1 Chapter 1: Introduction: Uracil misincorporation and thymine-less death – old and new hypotheses on the mechanism of action of antifolates and TS inhibitors ……………………………..3
    [Show full text]
  • Study of Nucleoside Degrading Enzyme Activities in Bean, Organic Bean, Okra, Organic Okra, Squash and Organic Squash
    STUDY OF NUCLEOSIDE DEGRADING ENZYME ACTIVITIES IN BEAN, ORGANIC BEAN, OKRA, ORGANIC OKRA, SQUASH AND ORGANIC SQUASH by Shafiqa A. Alshaiban A Thesis Submitted in Partial Fulfillment of the Requirements for the Degree of Master of Science in Chemistry Middle Tennessee State University August 2016 Thesis Committee: Dr. Paul C. Kline, Chair Dr. Andrew Burden Dr. Anthony Farone I dedicate this research to my parents, my sisters, and my brothers. I love you all. ii ACKNOWLEDGEMENTS I would like to sincerely thank Dr. Paul Kline for the support and guidance he has offered throughout the entirety of the research and thesis writing process. I also wish to thank my committee members, Dr. Donald A. Burden and Dr. Anthony Farone for their advice and willingness to read my work. I would like to thank all the staff and faculty members for their valuable support. Finally, I would like to express my thanks to my family and my friends for their support and love. Special thanks to my loving parents, my brothers and my sisters for their prayer, concern and kind words over the years. iii ABSTRACT Pyrimidine and purine nucleotide metabolism are essential for development and growth of all organisms. Nucleoside degradation reactions have been found in virtually all organisms. Many enzymes are involved in the degradation and salvage of nucleotides, nucleobases and nucleosides. Deaminases contribute in interconversion of one nucleoside into another by removing amino groups from the base. Nucleoside hydrolase is a glycosidase that catalyzes the cleavage of the N-glycosidic bond in nucleosides to facilitate recycling of nucleobases.
    [Show full text]
  • Nucleotides, Nucleic Acids: General Information About Structure, Functions and Metabolism
    MINISTRY OF HEALTH OF UKRAINE ZAPORIZHZHIA STATE MEDICAL UNIVERSITY Biological Chemistry Department Nucleotides, Nucleic acids: General Information about Structure, Functions and Metabolism A manual for independent work at home and in class for students of second year study of international faculty Speciality “Medicine” Zaporizhzhia, 2016 1 UDC 577.1(075.8) BBC 28.902я73 N92 The manual was approved on the Central Methodological Council of ZSMU on «____» _______________2016, the protocol №________ Reviewers: Prykhodko O.B., Head of Medical Biology, Parasitology and Genetics Department of Zaporizhzhia State Medical University, doctor of biological science Voskoboynik O.Yu., associate professor of Organic and Bioorganic Chemistry Department of Zaporizhzhia State Medical University, PhD Editors: Dr. Hab., professor Aleksandrova K. V. PhD, assoc. professor Ivanchenko D. G. PhD, assoc. professor Krisanova N. V. Nucleotides, Nucleic acids : General Information about Structure, Functions and Metabolism : a manual for independent work at home and in class for students of second year study of international faculty, speciality ―Medicine‖/ ed. : K. V. Aleksandrova, D. G. Ivanchenko, N. V. Krisanova. – Zaporizhzhia : ZSMU, 2016.- 84 p. This manual is recommended to use for students of International Faculty (the second year of study) for independent work at home and in class. Нуклеотиди, нуклеїнові кислоти : загальне уявлення про структуру, функції та метаболізм : навч. посіб. для самостійної аудиторної та позааудиторної роботи студентів 2 курсу міжнар. ф-ту, спеціальність «Медицина» / ред.. : К. В. Александрова, Д. Г. Іванченко, Н. В. Крісанова. - Запоріжжя : ЗДМУ, 2016. – 84 с. UDC 577.1(075.8) BBC 28.902я73 ©Aleksandrova K.V., IvanchenkoD.G., Krisanova N.V., 2016 ©Zaporizhzhia State Medical University, 2016 2 INTRODUCTION A study of questions for this manual is the basis for learning of all metabolic pathways for nucleotides and nucleic acids.
    [Show full text]
  • 1 Synthesis of C-2 and C-6 Functionalized
    1 SYNTHESIS OF C-2 AND C-6 FUNCTIONALIZED RIBOFURANOSYLPURINE ANALOGUES AS POTENTIAL ANTIVIRAL AGENTS TARGETING INHIBITION OF INOSINE MONOPHOSPHATE DEHYDROGENASE. by Eric Osei-Tutu Bonsu (Under the Direction of Vasu Nair) ABSTRACT IMPDH is a key enzyme in the de novo biosynthesis of purine nucleotides. It catalyzes the conversion of inosine monophosphate (IMP) to xanthosine monophosphate (XMP) using NAD as a cofactor. XMP is successively converted to deoxyguanosine triphosphate (substrate for DNA synthesis) by GMP synthetase, phosphorylating enzymes and ribonucleotide reductase. IMPDH exists in two isoforms, type I and type II. These isoforms have the same size and share 84% homology. The type I isoform is expressed in both normal and rapidly proliferating cells, whereas type II is preferentially upregulated in proliferating cells. Inhibition of IMPDH has anticancer, antiviral, antibacterial and immunosuppressive effects. Three inhibitors of IMPDH are currently in clinical use: ribavirin (a broad spectrum antiviral), mizoribine (immunosuppressant used in Japan) and mycophenolic mofetil (prodrug of mycophenolic acid, US approved immunosuppressant). None of these inhibitors possess significant selectivity against the type II isoform over the type I, hence there are severe side effects. The quest for specific isozyme inhibitors led to the discovery of the potential antiviral activity of certain C-2 functionalized hypoxanthine and C-2, C-6 modified purine systems against HSV1, HSV2, VV, VSV and RSV. 2 Nair and coworkers have synthesized similar congeners, including 2-vinylinosine (broad spectrum antiviral), which is active due to its C-2 vinyl moiety acting as a Michael Acceptor. This dissertation elucidates the design and synthesis of new Michael Acceptor-type nucleosides.
    [Show full text]
  • Purines and Pyrimidines Panel, Urine
    FILE DEFINITION TEST CHANGE Notification Date: October 11, 2019 Effective Date: November 14, 2019 Purines and Pyrimidines Panel, Urine Test ID: PUPYU Explanation: On 11/14/19, a new reportable field for S-Sulfocysteine will be added to the test. The reference ranges for the test will also be updated to include the analyte. Collaborative Laboratory Integrated Reports (CLIR) images will be available for viewing via a Supplemental Report in Mayo Access. These images will be added to the report at the discretion of the signing consultant. Accessing Supplemental PDF Reports in Mayo Access - questions on this process can be directed to MCL Client Support. Current Result Codes New Result Codes Result ID Reporting Name Result ID Reporting Name 42201 Interpretation (PUPYU) 42201 Interpretation (PUPYU) 41978 Uracil 41978 Uracil 38249 Thymine 38249 Thymine 38239 Adenine 38239 Adenine 41980 Hypoxanthine 41980 Hypoxanthine 41981 Xanthine 41981 Xanthine 38246 Orotic Acid 38246 Orotic Acid 38251 Dihydroorotic 38251 Dihydroorotic 41979 Uric Acid 41979 Uric Acid 38252 Deoxythymidine 38252 Deoxythymidine 38253 Deoxyuridine 38253 Deoxyuridine 38248 Thymidine 38248 Thymidine 38250 Uridine 38250 Uridine 38241 Deoxyadenosine 38241 Deoxyadenosine 38243 Deoxyinosine 38243 Deoxyinosine © Mayo Foundation for Medical Education and Research. All rights reserved. 1 of 2 38242 Deoxyguanosine 38242 Deoxyguanosine 38240 Adenosine 38240 Adenosine 38245 Inosine 38245 Inosine 38244 Guanosine 38244 Guanosine 38254 AICAR 38254 AICAR 38247 Succinyladenosine 38247 Succinyladenosine
    [Show full text]